Literature DB >> 6234162

Immunologic mechanisms of parenchymal lung injury.

W F Willoughby, J B Willoughby.   

Abstract

The lung, like most other organs, is susceptible to injury by circulating immune complexes, and also by humoral autoantibody and immune lymphocytes which specifically recognize selected lung antigens. In addition, by virtue of its direct communication with the external environment, the lung can also be injured by inhaled environmental agents which trigger inflammatory reactions mediated by immune effector systems. Although major emphasis to date has been placed on the ability of inhaled antigens to first sensitize, then provoke, immunologically specific reactions in the lung, there is increasing evidence to show that these same immune effector systems are also triggered in an immunologically nonspecific fashion by a certain environmental agents (termed "mitogens") which activate leukocytes in a polyclonal fashion. Such agents include certain viruses and other microorganisms, bacterial endotoxin, a wide variety of plant lectins, and certain chemicals, such as the phorbol esters. Although such agents act in an immunologically nonspecific fashion, they are nonetheless quite specific from a chemical viewpoint, and in many cases act by binding to specific receptors on the cell surface. By activating macrophages directly, and by activating much larger percentages of a given lymphocyte population than do specific antigens, they induce correspondingly amplified inflammatory reactions in vivo. Recent studies with animal models indicate that inhaled mitogens are strikingly effective in inducing pulmonary inflammation, whereas inhaled antigens (lacking mitogenic activity) produce little if any parenchymal injury in immunized recipients, unless administered in conjunction with a mitogen. Ongoing studies using such models promise to provide valuable new insight into the biologic properties which govern the pathogenicity of inhaled environmental agents, the mediators they release, and the biochemical basis for variations in individual susceptibility to injury by such agents.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6234162      PMCID: PMC1568360          DOI: 10.1289/ehp.8455239

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  80 in total

Review 1.  Activation of the alternative complement pathway.

Authors:  D T Fearon
Journal:  CRC Crit Rev Immunol       Date:  1979-11

Review 2.  Immunopathology of allergic lung disease.

Authors:  J Pepys
Journal:  Clin Allergy       Date:  1973-03

3.  Loss of macromolecular barrier function associated with surgical trauma to the intestine.

Authors:  R S Rhodes; M J Karnovsky
Journal:  Lab Invest       Date:  1971-09       Impact factor: 5.662

4.  Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis.

Authors:  H Y Reynolds; J D Fulmer; J A Kazmierowski; W C Roberts; M M Frank; R G Crystal
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

5.  Circulating immunoglobulin complexes in Wegener's granulomatosis.

Authors:  S B Howell; W V Epstein
Journal:  Am J Med       Date:  1976-02       Impact factor: 4.965

Review 6.  Complement-induced granulocyte aggregation: an unsuspected mechanism of disease.

Authors:  H S Jacob; P R Craddock; D E Hammerschmidt; C F Moldow
Journal:  N Engl J Med       Date:  1980-04-03       Impact factor: 91.245

7.  Experimental anti-alveolar basement membrane antibody-mediated pneumonitis. I. The role of increased permeability of the alveolar capillary wall induced by oxygen.

Authors:  L Jennings; O A Roholt; D Pressman; M Blau; G A Andres; J R Brentjens
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

Review 8.  A review of recent contributions on biologically active products of arachidonate conversion.

Authors:  R A Lewis; J M Drazen; J C Figueiredo; E J Corey; K F Austen
Journal:  Int J Immunopharmacol       Date:  1982

9.  Acute immunologic pulmonary alveolitis.

Authors:  K J Johnson; P A Ward
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

10.  Experimental immune complex disease of the lung. The pathogenesis of a laboratory model resembling certain human interstitial lung diseases.

Authors:  J R Brentjens; D W O'Connell; I B Pawlowski; K C Hsu; G A Andres
Journal:  J Exp Med       Date:  1974-07-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Polyclonal activators in pulmonary immune disease.

Authors:  W F Willoughby; J B Willoughby; G F Gerberick
Journal:  Clin Rev Allergy       Date:  1985-05

2.  Serum factor requirement for reactive oxygen intermediate release by rabbit alveolar macrophages.

Authors:  G F Gerberick; J B Willoughby; W F Willoughby
Journal:  J Exp Med       Date:  1985-02-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.